Amgen drug combo cuts death risk 58% in lung cancer
CNBC · RSS · · AI-summarised by FinFlash
Amgen said its drug, added to an AstraZeneca immunotherapy, cut the risk of death by 58% in patients with an aggressive form of lung cancer and could give them significantly more time to live. The combination pairs two companies' oncology assets in a hard-to-treat setting. For investors, the data support Amgen's oncology pipeline and AstraZeneca's immunotherapy franchise.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.